Roderick J Tan Selected Research

Roderick J Tan Research Topics

Disease

16	Fibrosis (Cirrhosis) 01/2021 - 11/2004
8	Inflammation (Inflammations) 01/2015 - 11/2004
7	Kidney Diseases (Kidney Disease) 01/2022 - 06/2012
6	Chronic Renal Insufficiency 01/2022 - 02/2012
6	Proteinuria 01/2021 - 01/2013
6	Acute Kidney Injury (Acute Renal Failure) 01/2020 - 06/2012
5	Pulmonary Fibrosis (Fibrosing Alveolitis) 03/2008 - 11/2004
4	Albuminuria 01/2019 - 01/2013
4	Asbestosis 02/2008 - 11/2004
4	Lung Injury 09/2006 - 11/2004
3	Reperfusion Injury 01/2020 - 09/2013
3	Wilms Tumor (Wilm's Tumor) 11/2018 - 01/2015
3	Ureteral Obstruction 01/2018 - 04/2013
3	Pneumonia (Pneumonitis) 02/2008 - 02/2006
3	Interstitial Lung Diseases (Interstitial Lung Disease) 02/2008 - 11/2004
2	Hypertension (High Blood Pressure) 01/2019 - 01/2019
2	Disease Progression 10/2015 - 09/2006
2	Focal Segmental Glomerulosclerosis (Glomerulosclerosis, Focal) 01/2013 - 02/2012
2	Idiopathic Pulmonary Fibrosis 03/2008 - 08/2005
1	Foot Injuries (Foot Injury) 01/2021
1	Sickle Cell Anemia (Hemoglobin S Disease) 01/2020
1	Bipolar Disorder (Manic Depressive Psychosis) 01/2020
1	Nephrogenic Diabetes Insipidus 01/2020
1	Pathologic Constriction (Stenosis) 01/2019
1	Wounds and Injuries (Trauma) 10/2015
1	Glomerulonephritis 06/2012
1	Diabetic Nephropathies (Diabetic Nephropathy) 06/2012
1	Acute Lung Injury 11/2004

Drug/Important Bio-Agent (IBA)

10	CateninsIBA 01/2019 - 02/2012
7	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2004
7	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 02/2012
5	CreatinineIBA 01/2019 - 01/2013
5	AntioxidantsIBA 11/2016 - 11/2004
5	Superoxide DismutaseIBA 10/2015 - 11/2004
5	AsbestosIBA 02/2008 - 11/2004
4	Matrix Metalloproteinase 7 (Matrilysin)IBA 01/2020 - 02/2012
3	Angiotensin IIIBA 01/2021 - 10/2015
3	nephrinIBA 01/2021 - 01/2015
3	EnzymesIBA 02/2008 - 11/2004
2	CollagenIBA 01/2019 - 01/2013
2	Plasminogen Activators (Plasminogen Activator)IBA 01/2019 - 11/2014
2	ICG 001IBA 01/2019 - 01/2015
2	AlbuminsIBA 10/2015 - 01/2013
2	Messenger RNA (mRNA)IBA 01/2013 - 02/2012
2	Matrix Metalloproteinases (MMPs)IBA 06/2012 - 09/2006
2	Heparin (Liquaemin)FDA LinkGeneric 02/2008 - 02/2006
2	Oxidants (Oxidizing Agents)IBA 02/2008 - 08/2005
2	Reactive Oxygen Species (Oxygen Radicals)IBA 02/2006 - 11/2004
2	Bleomycin (Blenoxane)FDA LinkGeneric 02/2006 - 11/2004
1	intrinsic factor-cobalamin receptorIBA 01/2022
1	Low Density Lipoprotein Receptor-Related Protein-2IBA 01/2022
1	1- (2- cyano- 3,12- dioxooleana- 1,9- dien- 28- oyl) imidazoleIBA 01/2021
1	bardoxolone methylIBA 01/2021
1	HemopexinIBA 01/2020
1	salicylhydroxamic acid (SHAM)IBA 01/2020
1	LithiumIBA 01/2020
1	Fibronectins (Fibronectin)IBA 01/2019
1	Polytetrafluoroethylene (Teflon)FDA Link 01/2019
1	NitrogenIBA 01/2019
1	Urea (Carbamide)FDA LinkGeneric 01/2019
1	Protamines (Protamine Sulfate)FDA Link 11/2018
1	CXA-10IBA 03/2018
1	Interleukin-17 ReceptorsIBA 01/2018
1	Interleukin-17 (Interleukin 17)IBA 01/2018
1	TenascinIBA 03/2017
1	Small Interfering RNA (siRNA)IBA 03/2017
1	Glycoproteins (Glycoprotein)IBA 03/2017
1	Biomarkers (Surrogate Marker)IBA 01/2017
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 09/2016
1	NADPH Oxidases (NAD(P)H oxidase)IBA 10/2015
1	UbiquitinIBA 03/2015
1	NPHS2 proteinIBA 01/2015
1	cyclopamineIBA 10/2014
1	ChemokinesIBA 09/2013
1	Proto-Oncogene Proteins c-metIBA 09/2013
1	Cisplatin (Platino)FDA LinkGeneric 09/2013
1	AtrasentanIBA 01/2013
1	Peptide Hydrolases (Proteases)FDA Link 06/2012
1	Hydroxyproline (4 Hydroxyproline)IBA 03/2008
1	Receptor for Advanced Glycation End ProductsIBA 03/2008
1	Heparitin Sulfate (Heparan Sulfate)IBA 02/2008
1	Matrix Metalloproteinase InhibitorsIBA 09/2006
1	N- (2(R)- 2- (hydroxamidocarbonylmethyl)- 4- methylpentanoyl)- L- tryptophan methylamideIBA 09/2006
1	Acetylcysteine (Siran)FDA LinkGeneric 08/2005
1	titanium dioxide (Titania)FDA Link 11/2004

Therapy/Procedure

2	Nephrectomy 01/2019 - 12/2015
2	Injections 10/2015 - 09/2006
2	Therapeutics 01/2015 - 08/2005
1	Denervation 01/2019
1	Renal Replacement Therapy (Therapies, Renal Replacement) 03/2018